research article

Radiological assessment of skeletal muscle index and myosteatosis and their impact postoperative outcomes after liver transplantation

Miha Petric[1,2], Taja Jordan[3], Popuri Karteek[4], Sabina Licen[5], Blaz Trotovsek[1,2], Ales Tomazic[1,2]

[1] Department of Abdominal Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia

[2] Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

[3] Institute of Radiology, University Medical Centre Ljubljana, Ljubljana, Slovenia

[4] Department of Computer Science, Memorial University of Newfoundland, St. John's, NL, Canada

[5] Faculty of Health Sciences, University of Primorska, Izola, Slovenia

Correspondence to: Miha Petrič; Department of Abdominal Surgery, University Medical Centre Ljubljana, Zaloška cesta 7, SI-1000 Ljubljana, Slovenia. E mail: miha.petric@kclj.si

Disclosure: No potential conflicts of interest were disclosed.

Background. Liver transplantation offers curative treatment to patients with acute and chronic end-stage liver disease. The impact of nutritional status on postoperative outcomes after liver transplantation remains poorly understood. The present study investigated the predictive value of radiologically assessed skeletal muscle index (SMI) and myosteatosis (MI) on postoperative outcomes.

Patients and methods. Data of 138 adult patients who underwent their first orthotopic liver transplantation were retrospectively analysed. SMI and MI in computer tomography (CT) scan at the third lumbar vertebra level were calculated. Results were analyzed for the length of hospitalisation and postoperative outcomes.

Results. In 63% of male and 28.9% of female recipients, low SMI was found. High MI was found in 45(32.6%) patients. Male patients with high SMI had longer intensive care unit (ICU) stay (P < 0.025). Low SMI had no influence on ICU stay in female patients (P = 0.544), length of hospitalisation (male, P > 0.05; female, P = 0.843), postoperative complication rates (males, P = 0.883; females, P = 0.113), infection rate (males, P = 0.293, females, P = 0.285) and graft rejection (males, P = 0.875; females, P = 0.135). The presence of MI did not influence ICU stay (P = 0.161), hospitalization (P = 0.771), postoperative complication rates (P = 0.467), infection rate (P = 0.173) or graft rejection rate (P = 0.173).

Conclusions. In our study, changes in body composition of liver transplant recipients observed with SMI and MI had no impact on postoperative course after liver transplantation. CT body composition analysis of recipients and uniformly accepted cut-off points are crucial to producing reliable data in the future.

Key words: muscle mass; liver transplantation; myosteatosis; skeletal muscle index; GLIM score

Introduction

Since 1963 when the first liver transplantation (LT) was performed by Starzl[1], it has become a standard treatment modality for patients with acute liver failure and chronic liver disease.[2] Ninety percent 5-year survival rate and better quality of life are the two most important outcomes of LT.[2] Most liver transplant centres use the Model for End-stage Liver Disease (MELD) score for organ allocation.[3] Patients with MELD score 15 or more, patients with poor quality of life due to chronic liver disease

symptoms (diuretic-intractable ascites, variceal bleeding, pruritus, cachexia), and patients with acute liver failure are those who benefit most from LT.[3] MELD score can underestimate the severity of liver disease in specific groups of patients (acute on chronic liver disease, presence of sarcopenia, chronic kidney disease, etc.).[3] Several modifications of the MELD score have been introduced, but none offers a more reliable and accurate scoring system. Albumin-bilirubin (ALBI) score is mainly used as an objective method to assess liver function and predict postoperative complications, particularly after hepatectomy in patients with hepatocellular carcinoma (HCC).[4] Its role in determining post-LT outcomes is not yet determined. Two main objective parameters of nutritional status are sarcopenia and myosteatosis (MI). The European Working Group on Sarcopenia defines sarcopenia as the presence of low muscle mass (under the 5th percentile) and low muscle function (strength or performance) in patients with advanced age, cancer, or other diseases.[5,6] Myosteatosis is defined as the abnormal fatty transformation of skeletal muscle. It negatively affects muscle strength and is common in advanced age[7,8], diabetes[7,8], obesity[9,10], chronic[9], and malignant diseases.[11,12] Overview of the literature shows large number of different methods used for body composition assessment in patients with liver cirrhosis.[13] There is still no consensus on the best tools for each body component in patients with liver cirrhosis. Most frequently used are computed tomography (CT), bioimpedance analysis (BIA), dual-energy X-ray absorptiometry (DXA) and anthropometry.[13] Some of them BIA, DXA and body mass index (BMI)) are not applicable in patients with end-stage liver disease due to frequent water retention.[14,15] In the last decade, computed tomography with automated or semiautomated body composition analysis at the third lumbar vertebra has emerged as an objective method of defining the nutritional status of patients with chronic liver disease.[15,16] Nutritional assessment with CT is not affected by water retention or presence of ascites. Skeletal muscle volume and myosteatosis can be measured from CT images obtained as a part of routine pre-transplant evaluation.[14] Skeletal muscle mass index (SMI) is calculated as muscle mass area divided by the square of the height. The Global Leadership Initiative on Malnutrition (GLIM)[16] score was introduced as a potential nutritional assessment tool in recent years. It was shown to have good predictive value as a risk assessment tool for postoperative morbidity and mortality in patients after colorectal sur-

gery.[17] However, its role as a predictive factor in LT is not yet established.

This study aimed to investigate feasibility of radiological assessment of a nutritional status of a patient and the predictive value of SMI and MI on postoperative complications, length of hospitalization, liver graft rejection, and mortality. We further compared the predictive value of SMI and MI with MELD, ALBI, and GLIM scores.

Patients and methods

We retrospectively analyzed 138 adult patients who had first orthotropic LT from brain dead donors between 1.1.2012 and 1.1.2020 in our institution. We excluded patients who had re-LT procedure and those whose abdominal CT scan could not be obtained from data base or received reduced size and liver graft from donation after cardiac death (DCD) donor. From the medical database, we collected recipient age, gender, body mass index, underlying liver disease, presence of ascites, hepatocellular carcinoma (HCC), and laboratory parameters (serum levels of sodium, creatinine, albumin, protein, bilirubin, and International normalized ratio (INR)). We calculated MELD and ALBI scores from laboratory parameters. Among GLIM criteria, we used chronic liver failure and end-stage liver disease as etiologic and SMI or MI as phenotypic criteria. Length of intensive care unit (ICU) stay, hospitalization, postoperative complications according to Clavien-Dindo classification[18], infections, and 90-day mortality were collected from the database of liver recipients and analyzed. Diagnosis of liver rejections was confirmed with laboratory tests and histological examination of all liver graft specimens obtained by ultrasound-guided biopsy. Acute rejection was defined with 6 points or more according to the liver allograft fibrosis score.[19]

The Slovenian National Medical Ethics Committee approved our study design (approval number 0120–230/2018–10) and waived the need to obtain informed consent from participants.

CT-body composition analysis

Abdominal CT scans were obtained from the hospital database system. In case of multiple CT scans, we used last CT scan before LT procedure. A single slice of each patient at the level of the 3rd lumbar vertebrae was selected for automatic segmentation. CT scans were analysed using the "Automated Body Composition Analyzer using Computed to-

TABLE 1. Laboratory and clinical data of patients

Variable	Min	Max	IQR	SD	95% CI	
					Lower	Upper
BMI	15	38	6	4.775	25.13	26.74
Waiting time for liver transplantation (days)	1	691	166	151.311	108.44	159.38
Sodium	121	147	6	4.701	136.09	137.68
Creatinine	41	696	46	67.082	85.91	108.49
Albumin	10	62	10	7.674	31.28	33.86
Protein	23	89	12	11.494	65.80	69.74
Bilirubin	2	687	56	107.535	51.83	88.04
INR	1	4	1	.502	1.44	1.61
MELD score	7	46	9	6.700	14.30	16.56
ALBI score	-4	0	1.13	0.802	-1.87	-1.60

ALBI score = albumin-bilirubin score; BMI = body mass index; INR = international normalized ratio; IQR = Interquartile range; MELD score = model for end-stage liver disease score

TABLE 2. Aetiology of liver disease and incidence of myosteatosis

Variable		Myosteatosis	
		no	yes
Liver failure	Alcohol-related	32	28
	Virus-related	14	3
	Other	47	14
χ2		9.717	
Degrees of freedom (Df)		2	
p		0.008	

mography image Segmentation" (ABACS)[20] software, which uses predefined Hounsfield units (HU) values to recognize different tissues. ABACS uses HU values from −29 to +150 HU to assess and calculate the total cross-sectional area for muscular tissue (SMA – skeletal muscle area). The L3 skeletal muscles included the psoas muscle, the lumbar muscles, the erector spinae, the transversus abdominis muscle, the internal and external oblique muscles, and the rectus abdominis. SMI was calculated using the following formula: SMI = SMA (cm^2) / height2 (m^2)[9,21] and patients were divided into a group with lower SMI (men < 52.4 cm^2/m^2, women < 38 cm^2/m^2)[9,21] and another with normal SMI. MI was determined by the medium value of HU in a skeletal muscle area. We used recently defined threshold parameters for MI in a patient with a chronic liver disease (< 33 HU in patients with a BMI ≥ 25 kg/m^2 and < 41 HU in those with a

BMI < 25).[22-24] Based on previous literature findings and conclusions no adjustment for sex was made for MI.[23,24]

Statistical analysis

Data were analysed using SPSS for macOS, 26th edition. Descriptive statistics such as frequencies, percentages, mean/median, and standard deviations were used for description and summary. Because the data were not normally distributed, patient characteristics were compared between groups using the Kruskal-Wallis test and the Mann-Whitney U test. In addition, Spearman rank-order correlation and multiple linear regression were used to determine the relationship between variables and predict patient outcomes based on their characteristics and condition, as well as the chi-square independence test. A P-value ≤ 0.05 was considered statistically significant.

Results

Patients characteristics

Between 1.1.2012 and 1.1.2020, 138 patients (100 men and 38 women) met the criteria for inclusion in the study. The median age was 57.5 years (22 to 69 years). Table 1 provides general data on the population laboratory and clinical variables.

Sixty-one (61, 44.2%) patients had LT due to inherited or metabolic liver disease, 60 patients had alcoholic liver disease (43.5%), and 17 patients had virus-related liver disease (12.3%). At the time of LT, 80 (58%) patients had ascites, and 27 patients had HCC (19.4%).

Incidence of low SMI and MI

In our study group, 63% of male and 28.9% of female patients had low SMI. MI was present in 45 (32.6%) patients. We found no statistical significance between the aetiology of underlying liver disease and SMI ($P = 0.214$). The aetiology of liver disease had a statistically significant influence on the incidence of MI. Patients with alcoholic aetiology had more fatty infiltrated muscles than patients with other liver disease aetiologies ($P = 0.008$) (Table 2).

A Spearman's rank-order correlation was run to determine the relationship between the MI and BMI. There was a moderate, negative correlation between MI and BMI, which was statistically significant (rs = -0.597, p < 0.000).

Eighty patients (57.9%) had decompensated liver cirrhosis with the presence of ascites at the time of CT scan. The Mann-Whitney U test indicates that ascites significantly impacted patients' SMI. The presence of ascites correlated with low SMI ($P <$ 0.05, Figure 1) and had no impact on the incidence of MI ($P = 0.244$).

Presence of HCC in patients with liver disease (27 patients, 19.6%) had no influence on SMI ($P = 0.546$) or MI ($P = 0.174$).

Influence of low SMI on hospitalization

The Mann-Whitney U test indicates that male patients with normal or high SMI (> 52.4 cm^2/m^2) had a longer ICU length of stay ($P < 0.025$). Linear regression was calculated to predict ICU length of stay based on SMI. A significant regression equation was found ($F_{(1.96)} = 6.823$, $P = 0.010$) (Figure 2), with R^2 of 0.066. SMI was found to significantly predict length of ICU stay ($\beta = 0.258$; 95% CI 0.026, 0.189; $P = 0.010$). The predicted length of stay equals $-1.117+0.107$ (SMI) days when SMI is measured in cm^2/m^2. The ICU length of stay increased by 0.107 days for each cm^2/m^2 of SMI in the male population.

A Spearman's rank-order correlation showed no difference in hospitalization time between males with low or normal SMI. Mann-Whitney U test indicates statistically significant differences between low or normal SMI ($P < 0.05$) in more extended hospitalization in male patients with normal SMI. In addition, the linear regression analysis was performed to predict the length of hospital stay based on SMI in male patients; however, no statistically significant regression equation was found ($\beta = -0.031$; 95% CI -0.656, 0.480; $P > 0.05$). In the female population, we found no statistically significant influence of SMI on ICU length of stay ($\beta = -0.123$; 95% CI -0.741, 0.463; $P = 0.544$) and hospitalization time ($\beta = 0.013$; 95% CI 0.075, 0.941; $P = 0.843$).

Influence of MI on hospitalisation

The Mann-Whitney U test indicates that there were no differences among the groups (MI and no-MI) regarding the ICU length of stay ($P = 0.161$) or hospitalization ($P = 0.771$).

Influence of SMI and MI on postoperative complications

Postoperative complications of stage 2 or more by Clavien-Dindo classification[19] were present in 79 patients (57.2%). Infection occurred in 59 patients


FIGURE 1. Correlation between ascites and skeletal muscle index.

(42.8%), most commonly as intra-abdominal infection (50.8%), respiratory tract infection (23.7%) and urosepsis (6.8%). 5 (3.6%) patients developed critical illness myopathy. Surgical intervention was needed in 38% of patients with postoperative complications.

There was no statistically significant difference in the frequency of postoperative complications between males ($P = 0.883$) and females ($P = 0.113$) with low or normal SMI. The postoperative infection rate was similar in males ($P = 0.293$) and females ($P = 0.285$) with low or normal SMI. MI did not show significant influence on postoperative complications ($P = 0.839$) and infection rate ($P = 0.703$).


FIGURE 2. Scatter diagram showing a positive correlation between the intensive care unit length of stay (days) and skeletal muscle index.

Influence of SMI and MI on liver graft rejection

Rejection was diagnosed in 22 patients (16.1%), 20 in male and 2 in female patients. We found no statistically significant influence of SMI (males, $P = 0.875$; females, $P = 0.135$) and MI ($P = 0.449$) on liver graft rejection.

Influence of MELD and ALBI score on postoperative outcomes

The median MELD score was 14 (7 – 46). A Spearman's rank-order correlation was run to determine the relationship between the MELD score and ICU length of stay (days). There was a weak, positive correlation between the MELD score and ICU length of stay, which was statistically significant ($r_s = 0.261$, $P < 0.002$). There was no significant relationship between the MELD score and complication rate or length of hospitalization ($P > 0.05$).

There is a week, positive correlation between the ALBI score and ICU length of stay and hospitalisation time, which was statistically significant ($r_s = 0.279$, $P < 0.001$; $r_s = 0.197$; $P = 0.022$). There is no correlation between the ALBI score and postoperative complications.

GLIM score

GLIM score using skeletal muscle index as a phenotypic factor

We analyzed differences between patients who meets criteria for positive GLIM score (acute or chronic liver disease as etiological factor and skeletal muscle index as a phenotypic factor) and those with negative GLIM score regarding ICU length of stay, postoperative complications, rate of infections, graft rejections and mortality.

Based on the chi-square independence test, no association was found between the groups in postoperative complications ($\chi2(1) = 0.600$; $P = 0.438$), rate of infections ($\chi2(1) = 0.918$; $P = 0.338$), graft rejection ($\chi2(1) = 1.205$; $P = 0.272$), and mortality ($\chi2(1) = 0.232$; $P = 0.630$). In addition, there were no statistically significant differences in ICU length of stay between groups ($\chi2(14) = 15.125$; $P = 0.370$), based on the Mann-Whitney test.

GLIM score using myosteatosis as a phenotypic factor

We analyzed differences between patient who meets criteria for positive GLIM score (acute or chronic liver disease as etiological factor and my-osteatosis as a phenotypic factor) and those with negative GLIM score regarding ICU length of stay, postoperative complications, rate of infections, graft rejections and mortality.

Based on the chi-square independence test, there was no association between the groups in terms of postoperative complications ($\chi2(1) = 1.378$; $P = 0.242$), infection rate ($\chi2(1) = 2.921$; $P = 0.089$), graft rejection ($\chi2(1) = 0.873$; $P = 0.352$), and mortality ($\chi2(1) = 0.010$; $P = 0.922$). In addition, there were no statistically significant differences in ICU length of stay between groups ($\chi2(14) = 16.271$; $P = 0.297$), based on the Mann-Whitney test.

Multiple linear regression analysis

Multiple linear regression was calculated to predict ICU length of stay on SMI and infection. A significant regression equation was found ($F (2. 95) = 11.192$, $P < 0.000$), with R^2 of 0.191. SMI was found to significantly predict length of ICU stay ($\beta = 0.292$; 95% CI 0.045, 0.199; $P = 0.002$). The length of ICU stays increased by 0.122 days per cm^2/m^2 SMI in male patients with infection.

Mortality

In our study group, 5 (3.6%) patients died in the first 90 days after liver transplantation. Two patients died immediately after the procedure due to irreversible haemorrhagic shock with disseminated intravascular thrombosis and abdominal organ ischemia. The cause of death in three patients was sepsis with multiorgan failure in one patient (day 66), and severe postoperative bleeding, intraabdominal infection with liver abscess, and multiorgan failure in two patients (34 and 53 days). One year survival rate was 95%. Due to the small number of patients, statistical analysis was not performed.

Discussion

Malnutrition with skeletal muscle mass loss is a frequent complication in patients with chronic or end-stage liver disease.[25] The aetiology of malnutrition is multifactorial.[23] Insufficient calorie intake (early satiety, loss of appetite, alcohol consumption, diet restriction), metabolic abnormalities, catabolic state of metabolism, and malabsorption are the main contributors to muscle loss.[25,26] It affects from 30 to 70%[27,28] of patients with end-stage liver disease and up to 80%[27] of patients with alcohol-re-

lated liver disease. Myosteatosis affects more than half of patients with chronic liver disease.[9] In our patient population, we used selected parameters for low SMI (men < 52.4 cm²/m², women < 38 cm²/m²)[9,21] and MI (< 33 HU in patients with a BMI ≥ 25 kg/m² and < 41 HU in those with a BMI < 25).[22-24] These cut-off values were determined specifically for patients on LT waiting list are the most widely used in literature.[22-24] Low SMI was present in 63% of males and 28.9% of females. More than one-third of the patients (32.6%) had fatty infiltration of the skeletal muscle. Patients with alcoholic aetiology had more fat-infiltrated muscles than other aetiologies for end-stage liver disease (P < 0.008). Alterations in the metabolism of fatty acids, eating habits, and alcohol consumption probably result in fatty infiltration of skeletal muscle fibres. However, due to the small numbers of patients (3 patients) with non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD) in our study group, we cannot properly assess the relationship between the aetiology of underlying liver disease and the degree of MI.

Several studies have shown that sarcopenia and myosteatosis are associated with a higher incidence of postoperative complications, infection rate, duration of hospitalization, and mortality in a wide range of gastrointestinal cancers, including tumours of the hepatopancreatobiliary system.[29-32] Lack of a strictly defined patient population, different methods of measurement of muscle mass and function, and the absence of uniformly accepted cut-off points for patients with chronic or end-stage liver disease are the leading causes for wide ranges of sarcopenia incidence reported in the literature.[14,21,33] Therefore, the selected cut-off points for patients with cancer are used for evaluation, which may affect the quality of results.

Sarcopenia is associated with poorer outcomes in patients with chronic liver disease on the waitlist or after LT.[34,35] Patients with end-stage liver disease and sarcopenia have shorter survival than non-sarcopenic patients (22 ± 3 *vs.* 95 ± 22-month, P < 0.001).[9,36] The main cause of death in patients with end-stage liver disease is sepsis.[37] Incidence of sepsis as a cause of death is even higher in presence of sarcopenia (36% *vs.* 16%, P < 0.001) or myosteatosis (32% *vs.* 19%, P = 0.020).[9] Lower muscle mass is also associated with a higher incidence of hepatic encephalopathy in patients with end-stage liver disease.[38,39] On the other hand, a group from USA[40] showed that sarcopenic patients had a higher tendency for pulmonary complications than the non-sarcopenic group (38% *vs.* 18%, P = 0.100); however,

there was no significant difference in morbidity and mortality.

CT imaging is considered as the gold standard for body composition assessment. SMI calculated on the level of third lumbar vertebra is superior since it correlates best with the actual quantity of the muscles in the body.[41] It is not affected by ascites and is part of preoperative evaluation in patients with hepatocellular carcinoma or the complications of portal hypertension. The value of SMI as a predicting factor for postoperative morbidity and mortality is yet to be determined. However, it has been shown in several reports that it has a negative impact on postoperative outcomes. Lower values of SMI are associated with more significant postoperative mortality, higher infection risk, and postoperative complications, more extended intensive care unit stay, ventilator dependency, and higher waitlist mortality rates in patients with end-stage liver disease.[33,42,43] SMI as a predicting factor for higher mortality rate in patients with end-stage liver disease was superior to other nutritional assessment indicators, such as BMI, upper arm muscle circumference, and triceps skinfold thickness.[44] However, some other reports showed contrasting findings. Using SMI for prespecified definitions of sarcopenia had no impact on mortality or delisting from the transplant waitlist between patients with and without sarcopenia.[45] Length of hospitalization following LT, days of hospitalization during the first year post-LT, survival at one year, or overall survival was not different between sarcopenic and nonsarcopenic patients.[46] Low SMI alone was not associated with graft and patient survival (P = 0.273 and P = 0.278) after LT.[47] These conflicting results are probably due to heterogeneity of used specific cut-off points (sex, age, race) and lack of strictly defined parameters representative uniquely for patients with chronic liver disease. We found a negative correlation between BMI and SMI, probably due to high-volume ascites in the patient population This confirms findings that BMI is not suitable for body assessment in patients with end-stage liver disease. In our study, the presence of ascites was associated with significantly lower SMI (P < 0.05) in patients with end-stage liver disease but did not influence MI. There is a weak, positive correlation between SMI and ICU length of stay in male patients, which was statistically significant (rs = 0.226, P < 0.025). We speculate that the main reason is a more pronounced systemic inflammatory reaction to surgical stress in patients with preserved muscle mass. It is known that muscle mass is mandatory for the normal function of the

immune system.[48] Experience from Japan[49] shows a connection between low SMI and decreased incidence of graft rejection in living-donor liver transplantation. Analysis of our results shows no statistically significant difference in postoperative complications, rate of postoperative infection, and liver graft rejection rate between males and females with low or normal SMI ($P > 0.05$). BIA is commonly used technique in body composition analysis in every day clinical practice.[50] Its key parameters are resistance, reactance and phase angle (PA). PA is found to be associated with outcomes in different diseases and has been found to be useful for monitoring fluid changes and response to interventions.[50] The main limitation is the complexity of the determinants that requires its adjustment to the individual phenotypic diagnosis of each patient. Results can be affected by altered water and electrolyte balance, fluid retention and diuretic therapy.[50] DXA allows for the quantification of three body compartments (bone mass, fat mass, and bone fat-free mass (or lean mass)) based upon the differential tissue attenuation of X-ray photons.[51] However, it can be affected by presence of ascites.[52] Even though DXA can be modified to exclude influence of ascites or tissue oedema the correlation between the lean mass index and SMI was weaker ($\gamma = 0.29$, $p = 0.035$) and falsely high in patients with ascites before liver transplantation.[53] Main disadvantages of DXA compared to CT is inability to assess muscle mass quality (myosteatosis).[51]

Myosteatosis is a more clearly defined factor, and its influence is more uniformly established in literature.[54] However, there are many different cut off points (HU < 25 to HU < 39) reported in literature in patients with malignant disease.[55] Majority of reports uses a Martin cut-off point (< 33 HU in patients with a BMI ≥ 25 kg/m^2 and < 41 HU in those with a BMI < 25)[56] for determining presence of myosteatosis. Martin cut-off point is also recently defined threshold parameters for MI in a patient with a chronic liver disease.[22-24] It has been shown that severely ill patients with myosteatosis have a lower survival rate than those without fatty infiltration in muscles.[57] Myosteatosis negatively impacts the survival of patients with end-stage liver disease (28 ± 5 *vs.* 95 ± 22-month, $P < 0.001$)[9,36] and is associated with longer hospitalization and higher morbidity.[43] Patients with myosteatosis showed a higher mortality rate, most commonly due to respiratory and septic complication.[47] Myosteatosis had no influence on ICU length of stay ($P = 0.161$), hospitalisation ($P = 0.771$), postoperative complica-

tions ($P = 0.839$), infection rate ($P = 0.703$) and graft rejection ($P= 0.449$) in our patient population.

The nutritional status on the waitlist for LT as a possible risk factor is overlooked with the MELD score.[58] Another important limiting factor of the MELD score is using serum creatinine levels for score calculation.[3] Serum creatinine level may vary significantly and is influenced by chronic kidney disease, ascites, paracentesis, and the influence of gender and liver disease on skeletal muscle mass.[59] Variation of serum creatinine levels may affect the MELD score and underestimate the severity of liver disease.[58] Thus, several modifications of the MELD score were developed to incorporate the nutritional parameters. Body composition MELD (BC-MELD)[60] has a better predictive value for waiting list mortality than MELD score. MELD-sarcopenia score showed a positive predictive value in patients with a lower score (< 15) on the postoperative course; however, it was not useful in patients with MELD above 15.[61,62] Combining SMI in MELD in multivariate analysis (AUROC= 0.812) is significantly better than MELD alone (AUROC = 0.787) for predicting 5-year mortality ($P < 0.001$).[44] We found a weak, positive correlation between the MELD score and ICU length of stay (rs = 0.261, $P < 0.002$). ALBI score showed promising results in more accurate prediction of liver disease severity and mortality on waitlist compared to the Child-Pugh score; however, its predictive value was inferior to the MELD score.[63] Patients with pre-transplant ALBI grade 3 liver disease had increased mortality after LT.[64] We found a weak, positive correlation between the ALBI score and ICU length of stay and hospitalization time, which was statistically significant (rs = 0.279, $P < 0.001$; rs = 0.197; $P = 0.022$). We found no correlation between the ALBI score and postoperative complications. The GLIM score[16] was established as a potential assessment tool for evaluating patient nutritional status in recent years. Our results showed no difference between the patients who met GLIM criteria and those who did not, regarding ICU stay, length of hospitalization, postoperative complications, infection, and mortality.

We believe that nutritional status in a patient with end-stage liver disease is an essential aspect of pre-transplant workup. However, its precise role is not yet determined. LT is a complex surgical procedure influenced by numerous factors. In the early phase of LT, donor characteristics and comorbidities, quality of liver graft retrieval, liver graft quality, cold preservation duration, ischemic damage to the liver graft during static cold storage,

recipient medical conditions and comorbidities, surgical procedure, and early postoperative therapy are by our opinion the most essential factors. However, muscle mass status, muscle function and myosteatosis are crucial factors in a period of rehabilitation.[65]

Patient with cachexia or with high-risk (< 18.5 kg/m^2, Child-Pough C)[66] to lose muscle mass should be screened and involved in intensive but personalized nutritional support therapy. Nutritional requirements in end stage liver disease are 35 kcal/kg per day in non-obese patients (BMI 30 kg/m^2) and 1,2g/kg per day intake of proteins.[66] It is safe to calculate requirements based on the dry weight of a patients.[66] In presence of hepatic encephalopathy (HE), animal protein should be substituted with vegetable protein origin. Randomized control study[67] showed that substitution of animal protein with vegetable protein for a period of six months (30–35 kcal/kg/d,1.0–1.5 g/kg/d protein) improved neuropsychiatric performance in patients with minimal HE and decrease their risk of developing overt HE compared to no intervention. It is unreal to expect to gain muscle mass in cirrhotic patients, but muscle mass preservation should be focus of such nutritional interventions. There are several strategies to prevent muscle mass loss in patients with end stage liver disease. First strategy is nutritional supplementations. Patients should have frequent small meals to avoid prolong fasting period (> 6 h).[66,68,69] Enteral supplements with side branched amino acids should be administered.[66,68,69] Snacks rich in carbohydrates should be taken as a late-night snack.[66,68,69] Second, physical activity in a form of resistance and endurance exercise, is probably appropriate and beneficial.[70] Micronutrition, especially administration of fat-soluble vitamins[71] and ammonia lowering therapy[72] is also important. Role of immunonutrition in patient with end stage liver disease is not yet established.[66,73] Post-transplant screening is advised in all patients after liver transplantation.[66,73]

There are several drawbacks to our study. The two most important are the retrospective nature of data collection and the lack of functional assessment of recipients' muscles. Another factor that may influence results is the relatively small number of cases that may affect some results or may not produce statistical significance due to the complexity of the treatment and numerous factors that determine its outcome.

In conclusion radiological assessment of a patient's nutritional status at the third lumbar vertebra represents an objective and reproducible method. It should become a standard screening tool in patients with acute or chronic end-stage liver disease. Due to complexity of liver transplant procedure, liver graft and liver recipients' factors, it is difficult to established impact of a skeletal muscle index and myosteatosis on postoperative outcomes. However, nutritional interventions and physical activity should be part of the clinical pathway in patients with end-stage liver disease waiting for liver transplantation. Prospective randomized controlled studies are not possible due to ethical considerations; hence, standardization and uniformity in definitions, methods, and cut-off points are crucial to producing reliable data in the future.

Acknowledgments

References

1. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. *Surg Gynecol Obstet* 1963; **117:** 659-76. PMID: 14100514

2. Song AT, Avelino-Silva VI, Pecora RA, Pugliese V, D'Albuquerque LA, Abdala E. Liver transplantation: fifty years of experience. *World J Gastroenterol* 2014; **20:** 5363-74. doi: 10.3748/wjg.v20.i18.5363

3. Polyak A, Kuo A, Sundaram V. Evolution of liver transplant organ allocation policy: current limitations and future directions. *World J Hepatol* 2021; **13:** 830-9. doi: 10.4254/with.v13.i8.830

4. Deng M, Ng SWY, Cheung ST, Chong CCN. Clinical application of Albumin-Bilirubin (ALBI) scores: the current status. *Surgeon* 2020; **18:** 178-86. doi: 10.1016/j.surge.2019.09.002

5. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019; **48:** 16-31. doi: 10.1093/ageing/afy169

6. Reginster JY, Beaudart C, Al-Daghri N, Avouac B, Bauer J, Bere N, et al. Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. *Aging Clin Exp Res* 2021; **33:** 3-17. doi: 10.1007/s40520-020-01663-4

7. Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Mieyer P, et al. Health, aging, and body. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. *Am J Clin Nutr* 2009; **90:** 1579-85. doi: 10.3945/ajcn.2009.28047

8. Miljkovic I, Kuipers AL, Cvejkus R, Bunker CH, Patrick AL, Gordon CL, el al. Myosteatosis increases with aging and is associated with incident diabetes in African ancestry men. *Obesity* 2016; **24:** 476-82. doi: 10.1002/oby.21328

9. Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CM, Sawyer MB, Beaumont C, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. *J Cachexia Sarcopenia Muscle* 2015; **7:** 126-35. doi: 10.1002/jcsm.12039

10. Goodpaster BH, Theriault R, Watkins SC, Kelley DE. Intramuscular lipid content is increased in obesity and decreased by weight loss. *Metabolism* 2000; **49:** 467-72. doi: 10.1016/s0026-0495(00)80010-4

11. Lee CM, Kang J. Prognostic impact of myosteatosis in patients with colorectal cancer: a systematic review and meta-analysis. *J Cachexia Sarcopenia Muscle* 2020; **11:** 1270-82. doi: 10.1002/jcsm.12575

12. Srpcic M, Jordan T, Popuri K, Sok M. Sarcopenia and myosteatosis at presentation adversely affect survival after esophagectomy for esophageal cancer. *Radiol Oncol* 2020; **54:** 237-46. doi: 10.2478/raon-2020-0016

13. Espinosa-Flores AJ, Guzman-Ortiz E, Melendez-Mier G, Ternovoy SK, Bueno-Hernandez N, Roldan-Valadez E. A scoping review of the methods used in patients with liver cirrhosis to assess body composition and their nutritional findings. [Ahead of print]. *Eur J Clin Nutr* 2023. doi:10.1038/s41430-023-01287-7

14. Lee CM, Kang BK, Kim M. Radiologic definition of sarcopenia in chronic liver disease. *Life (Basel)* 2021; **11:** 86. doi: 10.3390/life11020086

15. Kjønigsen LJ, Harneshaug M, Fløtten AM, Karterud LK, Petterson K, Skjolde G, et al. Reproducibility of semiautomated body composition segmentation of abdominal computed tomography: a multiobserver study. *Eur Radiol Exp* 2019; **3:** 42. doi: 10.1186/s41747-019-0122-5

16. Jensen GL, Cederholm T, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community. *JPEN J Parenter Enteral Nutr* 2019; **43:** 32-40. doi: 10.1002/jpen.1440

17. Song HN, Wang WB, Luo X, Huang DD, Ruan XJ, Xing CG, et al. Effect of GLIM-defined malnutrition on postoperative clinical outcomes in patients with colorectal cancer. *Jpn J Clin Oncol* 2022; **52:** 466-74. doi: 10.1093/jjco/hyab215

18. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004; **240:** 205-13. doi: 10.1097/01.sla.0000133083.54934.ae

19. Venturi C, Sempoux C, Bueno J, Ferreres Pinas JC, Bourdeaux C, Abarca-Quinones J, et al. Novel histologic scoring system for long-term allograft fibrosis after liver transplantation in children. *Am J Transplant* 2012; **12:** 2986-96. doi: 10.1111/j.1600-6143.2012.04210.x

20. Popuri K, Cobzas D, Esfandiari N, Baracos V, Jagersand M. Body composition assessment in axial CT images using FEM-based automatic segmentation of skeletal muscle. *IEEE Trans Med Imaging* 2016; **35:** 512-20. doi: 10.1109/TMI.2015.2479252

21. van Vugt JL, Levolger S, de Bruin RW, van Rosmalen J, Metselaar HJ, IJzermans JN. Systematic review and meta-analysis of the impact of computed tomography-assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. *Am J Transplant* 2016; **16:** 2277-92. doi: 10.1111/ajt.13732

22. Ebadi M, Tsien C, Bhanji RA, Dunichand-Hoedl AR, Rider E, Motamedrad M, et al. Myosteatosis in cirrhosis: a review of diagnosis, pathophysiological mechanisms and potential interventions. *Cells* 2022; **11:** 1216. doi: 10.3390/cells11071216

23. Eslamparast T, Montano-Loza AJ, Raman M, Tandon P. Sarcopenic obesity in cirrhosis – the confluence of 2 prognostic titans. *Liver Int* 2018; **38:** 1706-17. doi: 10.1111/liv.13876

24. Czigany Z, Kramp W, Bednarsch J, van der Kroft G, Boecker J, Strnad P, et al. Myosteatosis to predict inferior perioperative outcome in patients undergoing orthotopic liver transplantation. *Am J Transplant* 2020; **20:** 493-503. doi: 10.1111/ajt.15577

25. Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. *J Hepatol* 2016; **65:** 1232-44. doi: 10.1016/j.jhep.2016.07.040

26. Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. J *Gastroenterol* 2019; **54:** 845-59. doi:10.1007/s00535-019-01605-6

27. Montano-Loza AJ. Skeletal muscle abnormalities and outcomes after liver transplantation. *Liver Transpl* 2014; **20:** 1293-95. doi: 10.1002/lt.23995

28. Kim HY, Jang JW. Sarcopenia in the prognosis of cirrhosis: going beyond the MELD score. *World J Gastroenterol* 2015; **21:** 7637-47. doi: 10.3748/wjg.v21.i25.7637

29. Levolger S, van Vugt JLA, de Bruin RWF, IJzermans JNM. Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreatobiliary malignancies. *Br J Surg* 2015; **102:** 1448-58. doi: 10.1002/bjs.9893

30. Cao Q, Xiong Y, Zhong Z, Ye Q. Computed tomography-assessed sarcopenia indexes predict major complications following surgery for hepatopancreatobiliary malignancy: a meta-analysis. *Ann Nutr Metab* 2019; **74:** 24-34. doi: 10.1159/000494887

31. Kaibori M, Ishizaki M, Iida H, Matsui K, Sakaguchi T, Inoue K, et al. Effect of intramuscular adipose tissue content on prognosis in patients undergoing hepatocellular carcinoma resection. *J Gastrointest Surg* 2015; **19:** 1315-23. doi: 10.1007/s11605-015-2838-8

32. Ooi PH, Hager A, Mazurak VC, Dajani K, Bhargava R, Gilmour SM, et al. Sarcopenia in chronic liver disease: impact on outcomes. *Liver Transpl* 2019; **25:** 1422-38. doi: 10.1002/lt.25591

33. Weerink LBM, van der Hoorn A, van Leeuwen BL, de Bock GH. Low skeletal muscle mass and postoperative morbidity in surgical oncology: a systematic review and meta-analysis. *J Cachexia Sarcopenia Muscle* 2020; **11:** 636-49. doi: 10.1002/jcsm.12529

34. Hsu CS, Kao JH. Sarcopenia and chronic liver diseases. *Expert Rev Gastroenterol Hepatol* 2018; **12:** 1229-44. doi: 10.1080/17474124.2018.1534586

35. Pinto Dos Santos D, Kloeckner R, Koch S, Hoppe-Lotichius M, Zöller D, Toenges G, et al. Sarcopenia as prognostic factor for survival after orthotopic liver transplantation. *Eur J Gastroenterol Hepatol* 2020; **32:** 626-34. doi: 10.1097/MEG.0000000000001552

36. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2012; **10:** 166-73, 173.e1. doi: 10.1016/j.cgh.2011.08.028

37. Lucidi C, Lattanzi B, Di Gregorio V, Incicco S, D'Ambrosio D, Venditti M, et al. A low muscle mass increases mortality in compensated cirrhotic patients with sepsis. *Liver Int* 2018; **38:** 851-7. doi: 10.1111/liv.13691

38. Chang KV, Chen JD, Wu WT, Huang KC, Lin HY, Han DS. Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis. *J Formos Med Assoc* 2019; **118:** 833-42. doi: 10.1016/j.jfma.2018.09.011

39. Lattanzi B, D'Ambrosio D, Merli M. Hepatic encephalopathy and sarcopenia: two faces of the same metabolic alteration. *J Clin Exp Hepatol* 2019; **9:** 125-13. doi: 10.1016/j.jceh.2018.04.007

40. Dhaliwal A, Larson D, Hiat M, Muinov LM, Harrison WL, Sayles H, et al. Impact of sarcopenia on mortality in patients undergoing liver re-transplantation. *World J Hepatol* 2020; **12:** 807-15. doi: 10.4254/wjh.v12.i10.807

41. Lee CM, Kang BK, Kim M. Radiologic definition of sarcopenia in chronic liver disease. *Life* 2021; **11:** 86. doi: 10.3390/life11020086

42. Meeks AC, Madill J. Sarcopenia in liver transplantation: a review. *Clin Nutr ESPEN* 2017; **22:** 76-80. doi: 10.1016/j.clnesp.2017.08.005

43. van Vugt JL, Levolger S, de Bruin RW, van Rosmalen J, Metselaar HJ, IJzermans JN. Systematic review and meta-analysis of the impact of computed tomography-assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. *Am J Transplant* 2016; **16:** 2277-92. doi: 10.1111/ajt.13732

44. Yao J, Zhou X, Yuan L, Niu LY, Zhang A, Shi H, et al. Prognostic value of the third lumbar skeletal muscle mass index in patients with liver cirrhosis and ascites. *Clin Nutr* 2020; **39:** 1908-13. doi: 10.1016/j.clnu.2019.08.006

45. Kappus MR, Wegermann K, Bozdogan E, Patel YA, Janas G, Shropshire E, et al. Use of skeletal muscle index as a predictor of wait-list mortality in patients with end-stage liver disease. *Liver Transpl* 2020; **26:** 1090-9. doi: 10.1002/lt.25802

46. Aby ES, Lee E, Saggi SS, Viramontes MR, Grotts JF, Agopian VG, et al. Pretransplant sarcopenia in patients with NASH cirrhosis does not impact rehospitalization or mortality. *J Clin Gastroenterol* 2019; **53:** 680-5. doi: 10.1097/MCG.0000000000001109

47. Czigany Z, Kramp W, Lurje I, Miller H, Bednarsch J, Lang SA, et al. The role of recipient myosteatosis in graft and patient survival after deceased donor liver transplantation. *J Cachexia Sarcopenia Muscle* 2021; **12:** 358-67. doi: 10.1002/jcsm.12669

48. Nelke C, Dziewas R, Minnerup J, Meuth SG, Ruck T. Skeletal muscle as potential central link between sarcopenia and immune senescence. *EBioMedicine* 2019; **49:** 381-8. doi: 10.1016/j.ebiom.2019.10.034

49. Wakabayashi T, Shinoda M, Obara H, Kitago M, Yagi H, Abe Y, et al. Decreased incidence of acute cellular rejection in low-muscle-mass recipients after living-donor liver transplantation. *Transplant Proc* 2018; **50:** 3626-34. doi: 10.1016/j.transproceed.2018.06.028

50. Bellido D, García-García C, Talluri A, Lukaski HC, García-Almeida JM. Future lines of research on phase angle: strengths and limitations. *Rev Endocr Metab Disord* 2023; **24:** 563-83. doi: 10.1007/s11154-023-09803-7

51. Lee CM, Kang BK, Kim M. Radiologic definition of sarcopenia in chronic liver disease. *Life* 2021; **11:** 86. doi: 10.3390/life11020086

52. Kallwitz ER. Sarcopenia and liver transplant: the relevance of too little muscle mass. *World J Gastroenterol* 2015; **21:** 10982-93. doi: 10.3748/wjg. v21.i39.10982

53. Lindqvist C, Brismar TB, Majeed A, Wahlin S. Assessment of muscle mass depletion in chronic liver disease: dual-energy x-ray absorptiometry compared with computed tomography. *Nutrition* 2019; **61:** 93-8. doi: 10.1016/j. nut.2018.10.031

54. Shenvi SD, Taber DJ, Hardie AD, Botstein JO, McGillicuddy JW. Assessment of magnetic resonance imaging derived fat fraction as a sensitive and reliable predictor of myosteatosis in liver transplant recipients. *HPB (Oxford)* 2020; **22:** 102-8. doi: 10.1016/j.hpb.2019.06.006

55. Ahn H, Kim DW, Ko Y, Ha J, Shin YB, Lee J, et al. Updated systematic review and meta-analysis on diagnostic issues and the prognostic impact of myosteatosis: a new paradigm beyond sarcopenia. *Ageing Res Rev* 2021; **70:** 101398. doi: 10.1016/j.arr.2021.101398

56. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. *J Clin Oncol* 2013; **31:** 1539-47. doi: 10.1200/JCO.2012.45.2722

57. Loosen SH, Schulze-Hagen M, Püngel T, Bündgens L, Wirtz T, Kather JN, et al. Skeletal muscle composition predicts outcome in critically Ill patients. *Crit Care Explor* 2020; **2:** e0171. doi: 10.1097/CCE.0000000000000171

58. Kim HY, Jang JW. Sarcopenia in the prognosis of cirrhosis: going beyond the MELD score. *World J Gastroenterol* 2015; **21:** 7637-47. doi: 10.3748/wjg. v21.i25.7637

59. Francoz C, Prié D, Abdelrazek W, Moreau R, Mandot A, Belghiti J, et al. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. *Liver Transpl* 2010; **16:** 1169-77. doi: 10.1002/lt.22128

60. Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Shirai H, Yao S, et al. Including body composition in MELD scores improves mortality prediction among patients awaiting liver transplantation. *Clin Nutr* 2020; **39:** 1885-92. doi: 10.1016/j.clnu.2019.08.012

61. Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, Baracos VE, Sawyer MB, Pang JX, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis. *Clin Transl Gastroenterol* 2015; **6:** e102. doi: 10.1038/ctg.2015.31

62. van Vugt JLA, Alferink LJM, Buettner S, Gaspersz MP, Bot D, Darwish Murad S, et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort. *J Hepatol* 2018; **68:** 707-14. doi: 10.1016/j. jhep.2017.11.030

63. Chedid MF, Picon RV, Chedid AD. ALBI and PALBI: novel scores for outcome prediction of cirrhotic outpatients awaiting liver transplantation. *Ann Hepatol* 2018; **17:** 906-7. doi: 10.5604/01.3001.0012.7190

64. Bernardi N, Chedid MF, Grezzana-Filho TJM, Chedid AD, Pinto MA, Leipnitz I, et al. Pre-transplant ALBI grade 3 is associated with increased mortality after liver transplantation. *Dig Dis Sci* 2019**; 64:** 1695-704. doi: 10.1007/ s10620-019-5456-6

65. Miarka M, Gibiński K, Janik MK, Główczyńska R, Zając K, Pacho R, et al. Sarcopenia-the impact on physical capacity of liver transplant patients. *Life* 2021; **11:** 740. doi: 10.3390/life11080740.

66. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. *J Hepatol* 2019; **70:** 172-93. doi: 10.1016/j.jhep.2018.06.024

67. Maharshi S, Sharma BC, Sachdeva S, Srivastava S, Sharma P. Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial. *Clin Gastroenterol Hepatol* 2016; **14:** 454-60. e453. doi: 10.1016/j.cgh.2015.09.028

68. Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. *J Gastroenterol* 2019; **54:** 845-59. doi: 10.1007/s00535-019-01605-6

69. Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. *J Hepatol* 2016; **65:** 1232-44. doi: 10.1016/j. jhep.2016.07.040

70. Berzigotti A, Albillos A, Villanueva C, Genesca J, Ardevol A, Augustin S, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. *Hepatology* 2017; **65:** 1293-305. doi: 10.1002/hep.28992

71. Stokes CS, Volmer DA, Grunhage F, Lammert F. Vitamin D in chronic liver disease. *Liver Int* 2013; **33:** 338-52. doi: 10.1111/liv.12106

72. Miarka M, Gibiński K, Janik MK, Główczyńska R, Zając K, Pacho R, et al. Sarcopenia-the Impact on physical capacity of liver transplant patients. *Life* 2021**; 11:** 740. doi: 10.3390/life11080740

73. Lei Q, Wang X, Zheng H, Bi J, Tan S, Li N. Peri-operative immunonutrition in patients undergoing liver transplantation: a meta-analysis of randomized controlled trials. *Asia Pac J Clin Nutr* 2015; **24:** 583-90. doi: 10.6133/apjcn.2015.24.4.20.